Skip to main content
Clinical Trials/NCT05839834
NCT05839834
Recruiting
Not Applicable

A Blinded Prospective Study on Development and Validation of the Blood Cell RNA-Based Cancer Detection

Wuhan Union Hospital, China1 site in 1 country5,000 target enrollmentFebruary 8, 2021
ConditionsNeoplasmsCancer

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Neoplasms
Sponsor
Wuhan Union Hospital, China
Enrollment
5000
Locations
1
Primary Endpoint
Accuracy of TOO prediction
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

Early diagnosis of cancer may provide patients with more treatment options and hopefully prolong survival. The purpose of this multi-center study is to collect peripheral blood from newly diagnosed cancer patients and healthy donors to establish a blood cell RNA-based model for the differentiation of cancer patients and healthy donors. The area under the receiver operating characteristic (AUROC), sensitivity and specificity of the test in the early detection of multiple cancers will be measured.

Registry
clinicaltrials.gov
Start Date
February 8, 2021
End Date
December 8, 2024
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Sponsor
Wuhan Union Hospital, China
Responsible Party
Principal Investigator
Principal Investigator

Zheng Wang, MD/PhD

Study chair, Clinical Professor

Wuhan Union Hospital, China

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Accuracy of TOO prediction

Time Frame: 1 year

Accuracy of the tissue of origin (TOO) prediction of a blood cell RNA-based cancer detection test

Sensitivity and specificity of cancer detection

Time Frame: 1 year

Sensitivity and specificity of the early detection of 30 types of cancers of a blood cell RNA-based cancer detection test

Study Sites (1)

Loading locations...

Similar Trials